Nissay Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Buy |
39,482
+2,584
| +7% | +$779K | 0.05% | 229 |
|
|
2026
Q1 | $12.2M | Buy |
36,898
+1,085
| +3% | +$369K | 0.06% | 191 |
|
|
2025
Q4 | $14.2M | Buy |
35,813
+19,238
| +116% | +$8.51M | 0.07% | 176 |
|
|
2025
Q3 | $7.56M | Buy |
16,575
+287
| +2% | +$117K | 0.04% | 249 |
|
|
2025
Q2 | $5.31M | Buy |
16,288
+74
| +0.5% | +$20.5K | 0.03% | 314 |
|
|
2025
Q1 | $4.38M | Buy |
16,214
+267
| +2% | +$68.6K | 0.03% | 336 |
|
|
2024
Q4 | $3.79M | Buy |
15,947
+324
| +2% | +$85.2K | 0.02% | 372 |
|
|
2024
Q3 | $4.3M | Sell |
15,623
-478
| -3% | -$124K | 0.03% | 349 |
|
|
2024
Q2 | $3.91M | Buy |
16,101
+524
| +3% | +$82.7K | 0.03% | 348 |
|
|
2024
Q1 | $2.33M | Buy |
15,577
+319
| +2% | +$53.2K | 0.02% | 459 |
|
|
2023
Q4 | $2.92M | Buy |
15,258
+485
| +3% | +$82.6K | 0.02% | 371 |
|
|
2023
Q3 | $2.62M | Buy |
14,773
+537
| +4% | +$102K | 0.02% | 376 |
|
|
2023
Q2 | $2.7M | Sell |
14,236
-280
| -2% | -$55.5K | 0.02% | 379 |
|
|
2023
Q1 | $2.91M | Sell |
14,516
-194
| -1% | -$40.8K | 0.03% | 351 |
|
|
2022
Q4 | $3.5M | Sell |
14,710
-48
| -0.3% | -$10.2K | 0.03% | 301 |
|
|
2022
Q3 | $2.95M | Buy |
14,758
+556
| +4% | +$106K | 0.03% | 321 |
|
|
2022
Q2 | $2.07M | Buy |
14,202
+179
| +1% | +$25.4K | 0.02% | 399 |
|
|
2022
Q1 | $2.29M | Buy |
14,023
+386
| +3% | +$58.8K | 0.02% | 432 |
|
|
2021
Q4 | $2.31M | Buy |
13,637
+371
| +3% | +$69K | 0.02% | 447 |
|
|
2021
Q3 | $2.5M | Buy |
13,266
+1,913
| +17% | +$359K | 0.02% | 403 |
|
|
2021
Q2 | $1.93M | Buy |
11,353
+270
| +2% | +$39.5K | 0.02% | 457 |
|
|
2021
Q1 | $1.56M | Sell |
11,083
-289
| -3% | -$43.5K | 0.02% | 492 |
|
|
2020
Q4 | $1.48M | Sell |
11,372
-168
| -1% | -$22.4K | 0.02% | 491 |
|
|
2020
Q3 | $1.68M | Buy |
11,540
+474
| +4% | +$67.4K | 0.03% | 398 |
|
|
2020
Q2 | $1.64M | Buy |
11,066
+1,455
| +15% | +$196K | 0.03% | 411 |
|
|
2020
Q1 | $1.05M | Buy |
9,611
+400
| +4% | +$46.2K | 0.03% | 438 |
|
|
2019
Q4 | $1.06M | Sell |
9,211
-82
| -0.9% | -$8.18K | 0.02% | 508 |
|
|
2019
Q3 | $747K | Buy |
9,293
+1,498
| +19% | +$119K | 0.02% | 570 |
|
|
2019
Q2 | $566K | Buy |
7,795
+233
| +3% | +$17.9K | 0.01% | 634 |
|
|
2019
Q1 | $707K | Buy |
7,562
+394
| +5% | +$33K | 0.02% | 578 |
|
|
2018
Q4 | $523K | Buy |
7,168
+507
| +8% | +$39K | 0.02% | 595 |
|
|
2018
Q3 | $583K | Buy |
6,661
+259
| +4% | +$26.1K | 0.02% | 613 |
|
|
2018
Q2 | $631K | Sell |
6,402
-5,075
| -44% | -$503K | 0.02% | 584 |
|
|
2018
Q1 | $1.37M | Buy |
11,477
+160
| +1% | +$20.6K | 0.04% | 358 |
|
|
2017
Q4 | $1.44M | Buy |
+11,317
| New | +$1.42M | 0.04% | 350 |
|
Other funds holding ALNY
Nissay Asset Management's ALNY Position: Q2 2026 in Review
Nissay Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 7% in Q2 2026, buying an estimated $779K and bringing the position to 39,482 shares worth $11.9M. The position accounts for 0.05% of the portfolio, ranked #229.
Nissay Asset Management first reported a position in ALNY in Q4 2017 and has held it in 35 quarters since. The position peaked at $14.2M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Nissay Asset Management held 39,482 shares of Alnylam Pharmaceuticals worth $11.9M as of Q2 2026.
- Nissay Asset Management bought 2,584 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $779K.
- Alnylam Pharmaceuticals made up 0.05% of Nissay Asset Management's portfolio in Q2 2026, its #229 holding.
- Nissay Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Nissay Asset Management's Alnylam Pharmaceuticals position peaked at $14.2M in Q4 2025.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.